HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.
Read original at benzingaStocks · News reference
8-K filing — Roivant Sciences Ltd. (ROIV)
Filed: 2026-08-28 AccNo: 0001140361-26-034854 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 28, 2026, 8:31 PM
- Checked
- Aug 28, 2026, 8:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Roivant's Priovant Says FDA Approved LISRAYA For Dermatomyositis In Adults, First Targeted Therapy For The Disease; Available In U.S. Immediately
Read original at benzingaWhy Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
Read original at benzinga